Literature DB >> 31957018

Genetic diagnoses in epilepsy: The impact of dynamic exome analysis in a pediatric cohort.

Anne Rochtus1,2, Heather E Olson1,3, Lacey Smith1, Louisa G Keith1, Christelle El Achkar1,3, Alan Taylor4, Sonal Mahida1, Meredith Park1, McKenna Kelly1, Catherine Shain1, Shira Rockowitz5, Beth Rosen Sheidley1, Annapurna Poduri1,3.   

Abstract

OBJECTIVE: We evaluated the yield of systematic analysis and/or reanalysis of whole exome sequencing (WES) data from a cohort of well-phenotyped pediatric patients with epilepsy and suspected but previously undetermined genetic etiology.
METHODS: We identified and phenotyped 125 participants with pediatric epilepsy. Etiology was unexplained at the time of enrollment despite clinical testing, which included chromosomal microarray (57 patients), epilepsy gene panel (n = 48), both (n = 28), or WES (n = 8). Clinical epilepsy diagnoses included developmental and epileptic encephalopathy (DEE), febrile infection-related epilepsy syndrome, Rasmussen encephalitis, and other focal and generalized epilepsies. We analyzed WES data and compared the yield in participants with and without prior clinical genetic testing.
RESULTS: Overall, we identified pathogenic or likely pathogenic variants in 40% (50/125) of our study participants. Nine patients with DEE had genetic variants in recently published genes that had not been recognized as epilepsy-related at the time of clinical testing (FGF12, GABBR1, GABBR2, ITPA, KAT6A, PTPN23, RHOBTB2, SATB2), and eight patients had genetic variants in candidate epilepsy genes (CAMTA1, FAT3, GABRA6, HUWE1, PTCHD1). Ninety participants had concomitant or subsequent clinical genetic testing, which was ultimately explanatory for 26% (23/90). Of the 67 participants whose molecular diagnoses were "unsolved" through clinical genetic testing, we identified pathogenic or likely pathogenic variants in 17 (25%). SIGNIFICANCE: Our data argue for early consideration of WES with iterative reanalysis for patients with epilepsy, particularly those with DEE or epilepsy with intellectual disability. Rigorous analysis of WES data of well-phenotyped patients with epilepsy leads to a broader understanding of gene-specific phenotypic spectra as well as candidate disease gene identification. We illustrate the dynamic nature of genetic diagnosis over time, with analysis and in some cases reanalysis of exome data leading to the identification of disease-associated variants among participants with previously nondiagnostic results from a variety of clinical testing strategies. Wiley Periodicals, Inc.
© 2020 International League Against Epilepsy.

Entities:  

Keywords:  epilepsy; genetics; phenotype; reanalysis; whole exome sequencing

Mesh:

Year:  2020        PMID: 31957018      PMCID: PMC7404709          DOI: 10.1111/epi.16427

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  39 in total

1.  The genetic landscape of infantile spasms.

Authors:  Jacques L Michaud; Mathieu Lachance; Fadi F Hamdan; Lionel Carmant; Anne Lortie; Paola Diadori; Philippe Major; Inge A Meijer; Emmanuelle Lemyre; Patrick Cossette; Heather C Mefford; Guy A Rouleau; Elsa Rossignol
Journal:  Hum Mol Genet       Date:  2014-04-29       Impact factor: 6.150

2.  Whole-exome sequencing improves the diagnosis yield in sporadic infantile spasm syndrome.

Authors:  S Dimassi; A Labalme; D Ville; A Calender; C Mignot; N Boutry-Kryza; J de Bellescize; C Rivier-Ringenbach; E Bourel-Ponchel; D Cheillan; T Simonet; K Maincent; M Rossi; M Till; S Mougou-Zerelli; P Edery; A Saad; D Heron; V des Portes; D Sanlaville; G Lesca
Journal:  Clin Genet       Date:  2015-07-30       Impact factor: 4.438

3.  Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia.

Authors:  Sarah Weckhuysen; Elise Marsan; Virginie Lambrecq; Cécile Marchal; Mélanie Morin-Brureau; Isabelle An-Gourfinkel; Michel Baulac; Martine Fohlen; Christine Kallay Zetchi; Margitta Seeck; Pierre de la Grange; Bart Dermaut; Alfred Meurs; Pierre Thomas; Francine Chassoux; Eric Leguern; Fabienne Picard; Stéphanie Baulac
Journal:  Epilepsia       Date:  2016-05-13       Impact factor: 5.864

4.  Copy number variation plays an important role in clinical epilepsy.

Authors:  Heather Olson; Yiping Shen; Jennifer Avallone; Beth R Sheidley; Rebecca Pinsky; Ann M Bergin; Gerard T Berry; Frank H Duffy; Yaman Eksioglu; David J Harris; Fuki M Hisama; Eugenia Ho; Mira Irons; Christina M Jacobsen; Philip James; Sanjeev Kothare; Omar Khwaja; Jonathan Lipton; Tobias Loddenkemper; Jennifer Markowitz; Kiran Maski; J Thomas Megerian; Edward Neilan; Peter C Raffalli; Michael Robbins; Amy Roberts; Eugene Roe; Caitlin Rollins; Mustafa Sahin; Dean Sarco; Alison Schonwald; Sharon E Smith; Janet Soul; Joan M Stoler; Masanori Takeoka; Wen-Han Tan; Alcy R Torres; Peter Tsai; David K Urion; Laura Weissman; Robert Wolff; Bai-Lin Wu; David T Miller; Annapurna Poduri
Journal:  Ann Neurol       Date:  2014-06-13       Impact factor: 10.422

5.  NR2F1 mutations cause optic atrophy with intellectual disability.

Authors:  Daniëlle G M Bosch; F Nienke Boonstra; Claudia Gonzaga-Jauregui; Mafei Xu; Joep de Ligt; Shalini Jhangiani; Wojciech Wiszniewski; Donna M Muzny; Helger G Yntema; Rolph Pfundt; Lisenka E L M Vissers; Liesbeth Spruijt; Ellen A W Blokland; Chun-An Chen; Richard A Lewis; Sophia Y Tsai; Richard A Gibbs; Ming-Jer Tsai; James R Lupski; Huda Y Zoghbi; Frans P M Cremers; Bert B A de Vries; Christian P Schaaf
Journal:  Am J Hum Genet       Date:  2014-01-23       Impact factor: 11.025

6.  Predicting functional effect of human missense mutations using PolyPhen-2.

Authors:  Ivan Adzhubei; Daniel M Jordan; Shamil R Sunyaev
Journal:  Curr Protoc Hum Genet       Date:  2013-01

7.  Spectrum of neurodevelopmental disease associated with the GNAO1 guanosine triphosphate-binding region.

Authors:  McKenna Kelly; Meredith Park; Ivana Mihalek; Anne Rochtus; Marie Gramm; Eduardo Pérez-Palma; Erika Takle Axeen; Christina Y Hung; Heather Olson; Lindsay Swanson; Irina Anselm; Lauren C Briere; Frances A High; David A Sweetser; Saima Kayani; Molly Snyder; Sophie Calvert; Ingrid E Scheffer; Edward Yang; Jeff L Waugh; Dennis Lal; Olaf Bodamer; Annapurna Poduri
Journal:  Epilepsia       Date:  2019-01-25       Impact factor: 5.864

Review 8.  Genetic testing in the epilepsies-developments and dilemmas.

Authors:  Annapurna Poduri; Beth Rosen Sheidley; Sara Shostak; Ruth Ottman
Journal:  Nat Rev Neurol       Date:  2014-04-15       Impact factor: 42.937

9.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

10.  Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy.

Authors:  Katherine L Helbig; Kelly D Farwell Hagman; Deepali N Shinde; Cameron Mroske; Zöe Powis; Shuwei Li; Sha Tang; Ingo Helbig
Journal:  Genet Med       Date:  2016-01-21       Impact factor: 8.822

View more
  23 in total

1.  Defining the phenotype of FHF1 developmental and epileptic encephalopathy.

Authors:  Marina Trivisano; Alessandro Ferretti; Elizabeth Bebin; Linda Huh; Gaetan Lesca; Aleksandra Siekierska; Ryo Takeguchi; Maryline Carneiro; Luca De Palma; Ilaria Guella; Kazuhiro Haginoya; Ruo Ming Shi; Atsuo Kikuchi; Tomoko Kobayashi; Julien Jung; Lieven Lagae; Mathieu Milh; Marie L Mathieu; Berge A Minassian; Antonio Novelli; Nicola Pietrafusa; Eri Takeshita; Marco Tartaglia; Alessandra Terracciano; Michelle L Thompson; Gregory M Cooper; Federico Vigevano; Laurent Villard; Nathalie Villeneuve; Gunnar M Buyse; Michelle Demos; Ingrid E Scheffer; Nicola Specchio
Journal:  Epilepsia       Date:  2020-07-09       Impact factor: 5.864

2.  [Progressive psychomotor regression for 2.5 years in a boy aged 5 years].

Authors:  Mao-Qiang Tian; Xiao-Xi Chen; Lei Li; Chang-Hui Lang; Juan Li; Jing Chen; Xiao-Hua Yu; Xiao-Mei Shu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15

Review 3.  Diagnostic Considerations in the Epilepsies-Testing Strategies, Test Type Advantages, and Limitations.

Authors:  Wei-Liang Chen; Heather C Mefford
Journal:  Neurotherapeutics       Date:  2021-09-16       Impact factor: 6.088

4.  Exome sequencing as first-tier genetic testing in infantile-onset pharmacoresistant epilepsy: diagnostic yield and treatment impact.

Authors:  Ponghatai Boonsimma; Chupong Ittiwut; Wuttichart Kamolvisit; Rungnapa Ittiwut; Wanna Chetruengchai; Chureerat Phokaew; Chalurmpon Srichonthong; Sathida Poonmaksatit; Tayard Desudchit; Kanya Suphapeetiporn; Vorasuk Shotelersuk
Journal:  Eur J Hum Genet       Date:  2022-10-05       Impact factor: 5.351

5.  Effectiveness and Safety of Oxcarbazepine vs. Levetiracetam as Monotherapy for Infantile Focal Epilepsy: A Longitudinal Cohort Study.

Authors:  Binyang Zhao; Shuang Liao; Xuefei Zhong; Yuanyuan Luo; Siqi Hong; Min Cheng; Jie Zhang; Tingsong Li; Li Jiang
Journal:  Front Neurol       Date:  2022-06-01       Impact factor: 4.086

Review 6.  'Channeling' therapeutic discovery for epileptic encephalopathy through iPSC technologies.

Authors:  Dina Simkin; Christina Ambrosi; Kelly A Marshall; Luis A Williams; Jordyn Eisenberg; Mennat Gharib; Graham T Dempsey; Alfred L George; Owen B McManus; Evangelos Kiskinis
Journal:  Trends Pharmacol Sci       Date:  2022-05       Impact factor: 17.638

7.  Clinico-radiological features, molecular spectrum, and identification of prognostic factors in developmental and epileptic encephalopathy due to inosine triphosphate pyrophosphatase (ITPase) deficiency.

Authors:  Marcello Scala; Saskia B Wortmann; Namik Kaya; Menno D Stellingwerff; Angela Pistorio; Emma Glamuzina; Clara D van Karnebeek; Cristina Skrypnyk; Katarzyna Iwanicka-Pronicka; Dorota Piekutowska-Abramczuk; Elżbieta Ciara; Frederic Tort; Beth Sheidley; Annapurna Poduri; Parul Jayakar; Anuj Jayakar; Jariya Upadia; Nicolette Walano; Tobias B Haack; Holger Prokisch; Hesham Aldhalaan; Ehsan G Karimiani; Yilmaz Yildiz; Ahmet C Ceylan; Teresa Santiago-Sim; Amy Dameron; Hui Yang; Mehran B Toosi; Farah Ashrafzadeh; Javad Akhondian; Shima Imannezhad; Hanieh S Mirzadeh; Shazia Maqbool; Aisha Farid; Mohamed A Al-Muhaizea; Meznah O Alshwameen; Lama Aldowsari; Maysoon Alsagob; Ashwaq Alyousef; Rawan AlMass; Aljouhra AlHargan; Ali H Alwadei; Maha M AlRasheed; Dilek Colak; Hanan Alqudairy; Sameena Khan; Matthew A Lines; M Ángeles García Cazorla; Antonia Ribes; Eva Morava; Farah Bibi; Shahzad Haider; Matteo P Ferla; Jenny C Taylor; Hessa S Alsaif; Abdulwahab Firdous; Mais Hashem; Chingiz Shashkin; Kairgali Koneev; Rauan Kaiyrzhanov; Stephanie Efthymiou; Queen Square Genomics; Thomas Schmitt-Mechelke; Andreas Ziegler; Mahmoud Y Issa; Hasnaa M Elbendary; Pasquale Striano; Fowzan S Alkuraya; Maha S Zaki; Joseph G Gleeson; Tahsin Stefan Barakat; Jorgen Bierau; Marjo S van der Knaap; Reza Maroofian; Henry Houlden
Journal:  Hum Mutat       Date:  2022-01-12       Impact factor: 4.700

8.  Characterization of the GABRB2-Associated Neurodevelopmental Disorders.

Authors:  Christelle M El Achkar; Merle Harrer; Lacey Smith; McKenna Kelly; Sumaiya Iqbal; Snezana Maljevic; Cristina E Niturad; Lisenka E L M Vissers; Annapurna Poduri; Edward Yang; Dennis Lal; Holger Lerche; Rikke S Møller; Heather E Olson
Journal:  Ann Neurol       Date:  2020-12-24       Impact factor: 11.274

Review 9.  Paroxysmal Movement Disorders.

Authors:  Susan Harvey; Mary D King; Kathleen M Gorman
Journal:  Front Neurol       Date:  2021-06-11       Impact factor: 4.003

10.  Diagnostic Yield and Cost-Effectiveness of "Dynamic" Exome Analysis in Epilepsy with Neurodevelopmental Disorders: A Tertiary-Center Experience in Northern Italy.

Authors:  Costanza Varesio; Simone Gana; Alessia Asaro; Elena Ballante; Raffaella Fiamma Cabini; Elena Tartara; Michela Bagnaschi; Ludovica Pasca; Marialuisa Valente; Simona Orcesi; Cristina Cereda; Pierangelo Veggiotti; Renato Borgatti; Enza Maria Valente; Valentina De Giorgis
Journal:  Diagnostics (Basel)       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.